Effect of bronchofiberscopic lavage with acetylcysteine instillation on refractory mycoplasma pneumoniae pneumonia in children: a retrospective clinical observation

支气管镜灌洗联合乙酰半胱氨酸滴注治疗儿童难治性肺炎支原体肺炎的疗效:一项回顾性临床观察

阅读:2

Abstract

BACKGROUND: Bronchofiberscopic lavage is a therapeutic treatment for mycoplasma infection. However, there are limited reports on the use of bronchofiberscopic lavage with acetylcysteine instillation. The aim of our study was to investigate the clinical effect of bronchofiberscopic lavage with acetylcysteine instillation on refractory mycoplasma pneumoniae pneumonia in children. METHODS: This was a retrospective study. Clinical and laboratory data were collected from 280 children hospitalized with MPP in the Department of Pulmonary and Critical Care Medicine at Kunming Children's Hospital from January 2021 to January 2023, and these were divided into two groups: the study group and the control group. Children in the control group were treated with anti-infective, antitussive, and antipyretic routine symptomatic treatment and nebulization of acetylcysteine suspension, while children in the study group were treated with bronchofiberscopic lavage with acetylcysteine instillation along with standard treatment as in the control group. The clinical characteristics, adverse reactions, pulmonary imaging changes, and laboratory examination indicators were compared between the two groups. RESULTS: The treatment effective rate and the absorption area of lung lesions in the study group were significantly higher than those in the control group (P < 0.05). Before treatment, there were no statistically significant differences in WBC, IgG, IgE, CRP, and IL-6 levels between the two groups (P > 0.05). After 7 days of treatment, IgG levels in both groups were higher than those before treatment, while WBC, IgE, CRP, and IL-6 levels were lower than those before treatment (P < 0.05). CONCLUSIONS: The bronchofiberscopic lavage with acetylcysteine instillation constitutes a safe and efficacious therapeutic regimen, which might alleviate the clinical symptoms experienced and reduce the levels of inflammatory factors for children with RMPP.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。